Key result
Higher body mass index (OR 1.06), female sex (OR 1.67), and higher total dosage of oxaliplatin (OR 2.39) were identified as significant predictors for the development of oxaliplatin-induced peripheral neuropathy.
Why the study?
Oxaliplatin causes acute and chronic neuropathy that affects quality of life, but effective strategies for managing oxaliplatin-induced peripheral neuropathy remain elusive.
Observational (n=322)
No
Odds Ratio: 2.39 (95% CI 1.67–3.42)
p-value: p=<0.0001
Higher BMI, female sex, and higher cumulative oxaliplatin dose are significant risk factors for developing oxaliplatin-induced peripheral neuropathy in cancer patients.
Predictor identification may aid OIPN risk stratification; leaves open need for prospective validation before guiding practice.
BACKGROUND: Oxaliplatin causes acute cold-induced neurotoxicity and chronic cumulative neuropathy, which can require dose modification and impacts quality of life. However, effective strategies for managing oxaliplatin-induced peripheral neuropathy (OIPN) among affected patients remain elusive. OBJECTIVE: This retrospective study aimed to identify predictors for the development of OIPN. METHODS: Participants comprised 322 cancer patients at our hospital who were receiving oxaliplatin between January 2017 and March 2021. For the regression analysis of factors associated with OIPN, variables were manually extracted from medical charts. The severity of OIPN was evaluated using the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 5. Multivariate ordered logistic regression analysis was performed to identify predictors for the development of OIPN. Optimal cut-off thresholds were determined using receiver operating characteristic analysis. Values of P <0.05 (2-tailed) were considered significant. RESULTS: Significant risk factors identified included higher body mass index (BMI) (odds ratio [OR] = 1.06, 95% confidence interval [CI] = 1.00-1.12; P = 0.043), female sex (OR = 1.67, 95%CI = 1.06-2.61; P = 0.026) and higher total dosage (OR = 2.39, 95%CI = 1.67-3.42; P = < 0.0001). CONCLUSION: High BMI, female sex and high total dosage were identified as significant predictors for the development of OIPN.
No takes yet. Share an insight, caveat, or question.
Kanbayashi et al. (2022) conducted an observational in Cancer (colorectal, pancreatic, or gastric) requiring oxaliplatin (n=322). Higher total dosage of oxaliplatin vs. Lower total dosage of oxaliplatin was evaluated on Development and severity of oxaliplatin-induced peripheral neuropathy (OIPN) (OR 2.39, 95% CI 1.67-3.42, p=<0.0001). Higher body mass index (OR 1.06), female sex (OR 1.67), and higher total dosage of oxaliplatin (OR 2.39) were identified as significant predictors for the development of oxaliplatin-induced peripheral neuropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: